Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
A recent international clinical trial published in the journal of The Lancet Rheumatology found that sarilumab 200 mg every 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback